Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The capsular oligosaccharide of Neisseria meningitidis serogroup C is a key bacterial surface antigen composed of alpha(2->9)-linked sialic acid residues. It acts as a critical virulence factor by forming a protective capsule that shields the pathogen from host complement-mediated killing and opsonophagocytosis, allowing the bacteria to survive in the bloodstream and cause invasive disease. This oligosaccharide is a primary target for immunotherapies and vaccines designed to prevent meningococcal meningitis and septicemia. In modern conjugate vaccines, these oligosaccharide epitopes are chemically linked to carrier proteins like CRM197 or tetanus toxoid to recruit T-cell help, converting a T-cell independent response into a robust, T-cell dependent immune response. This conjugation is essential for inducing high-affinity IgG antibodies and establishing long-term immunological memory, particularly in infants and young children. The resulting antibodies specifically recognize the capsular epitopes, facilitating bacterial clearance via complement activation and phagocytosis.
Vaccines containing this antigen induce the production of protective bactericidal antibodies (IgG) that promote complement-mediated lysis and opsonophagocytosis of Neisseria meningitidis serogroup C bacteria.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neisseria meningitidis serogroup C capsular oligosaccharide (MenC OS).